Autopsy report · NCT00244257

Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

“Study terminated due to low enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 2 years 11 months before it stopped.
• 10 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Genzyme, a Sanofi Company

Sponsor type

Industry

Conditions

Idiopathic Thrombocytopenic Purpura

Interventions

GMA161; GMA161; GMA161; GMA161; GMA161

Participants

10

Sites

6

Countries

United States

Trials that died the same way

• BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
  “Study was terminated due to low enrollment.” (98% match in meaning)
• A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
  “The study was terminated due to low enrollment.” (96% match in meaning)
• A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension
  “Study was terminated due to poor enrollment” (95% match in meaning)
• Use of Teriparatide to Accelerate Fracture Healing
  “The study was terminated due to poor enrollment.” (94% match in meaning)
• Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
  “The study is terminated due to lower enrollment” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.